What is Sequence Bio?
Sequence Bio is a biotechnology firm dedicated to revolutionizing drug discovery by addressing the high attrition rates in pharmaceutical R&D. The company employs a sophisticated systems biology approach, integrating multi-omics data with real-world patient information to construct bespoke discovery cohorts. This methodology is applied to both common and rare diseases, enabling Sequence Bio to collaborate with leading pharmaceutical and biotech entities to expedite research and development timelines. Strategically located in Newfoundland and Labrador, the company capitalizes on the founder effect to enhance the identification of impactful genetic variants, positioning itself at the forefront of precision medicine.
How much funding has Sequence Bio raised?
Sequence Bio has raised a total of $3.5M across 2 funding rounds:
Angel/Seed
$500K
Angel/Seed
$3M
Angel/Seed (2015): $500K, investors not publicly disclosed
Angel/Seed (2016): $3M led by Killick Capital, Data Collective, and Klister Credit
Key Investors in Sequence Bio
Killick Capital
Killick Capital is a private equity firm based in Atlantic Canada that focuses on partnering with local businesses and those in the aerospace sector, aiming to fund investments with substantial growth potential and long-term value creation.
Data Collective
Data Collective is a startup non-profit focused on building and supporting technology to help people find, understand, and share data, aiming to advance the knowledge and education of citizens everywhere.
Klister Credit
Klister Credit Corp operates within the Banking industry, headquartered in Toronto, Ontario, Canada, and is involved in providing financial services.
What's next for Sequence Bio?
The recent major strategic investment signals a pivotal growth phase for Sequence Bio, likely enabling the company to scale its operations, expand its research capabilities, and further validate its unique discovery platform. This capital infusion is expected to accelerate the progression of its drug candidates through the development pipeline and strengthen its partnerships within the pharmaceutical and biotech industries. Sequence Bio's focus on leveraging multi-omics and real-world data, combined with its strategic location, positions it for significant advancements in tackling complex diseases and reducing drug development failures.
See full Sequence Bio company page
